Immunodiagnostics News
-
Showcase
Primary Results of Onawa (Solti-1802) Trial: A Window Of Opportunity Trial Of Onapristone In Postmenopausal Women With Progesterone Receptor-Positive/Her2-Negative Early Breast Cancer
PGR is an estrogen-responsive gene and progesterone receptor (PR) expression, evaluated by immunohistochemistry (IHC), is used as a clinical biomarker of estrogen signaling and estrogen receptor (ER) functionality.1 Despite the well-studied role of PGR as mitogen and independent ER activator, anti-progestins for the treatment of BC have been poorly tested. While limited success for ...
-
4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
By 4D Path Inc.
-
Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. This antibody is used for research only, not for human, therapeutic ...
-
NCI and rutgers university open phase 1 clinical trials of t cell receptor therapy targeting KK-LC-1for multiple solid tumors
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) expressing malignancies, ...
-
Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts
Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics (“LightDeck”), a pioneer in innovative planar waveguide ...
-
Creative Enzymes Expands Its Service Offering with the Launch of Native Horseradish Peroxidase
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. Creative Enzymes recently announced the launch of Horseradish Peroxidase for research and industrial production. Horseradish peroxidase, abbreviated as HRP, is a single-chain polypeptide ...
-
Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). These recombinant antigens in immunoassays are suitable for the detection of IgG and IgM antibodies against EBV in blood ...
-
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a new study in the Journal of Molecular Diagnostics on the Idylla™ GeneFusion Assay (RUO) for rapid detection of targetable fusions involving ALK, ROS1, RET, and NTRK1/2/3 and MET exon 14 skipping mutations. The ...
By Biocartis NV
-
Fc Fusion Protein Production Service Now Available at Profacgen
Profacgen, a state-of-the-art protein service provider located in the USA, provides comprehensive one-stop services for pre-clinical drug development, aiming to evaluate and improve the efficacy and safety of new drug candidates. Now, Profacgen can provide soluble Fc fusion protein to applicate in various fields. Fc fusion protein refers to a new type of protein produced by using genetic ...
By Profacgen
-
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients with MRCLS) and the disease control rate was 85% As of the data cut-off, afami-cel has shown a favorable benefit:risk profile Translational data confirm ...
-
World-Renowned Cancer Oncologist, Health Consultant and Entrepreneur Dr. Nelson Teich Added to 4D Path’s Distinguished Advisory Board
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Nelson Teich, MD, MBA, MSc, has joined the company’s prestigious advisory board. A world-renowned oncologist, health consultant and entrepreneur in the field of clinical oncology, Teich will act as a global ambassador for 4D Path’s cloud-based, quantitative ...
By 4D Path Inc.
-
4D Path, University of Leeds Extend Contract to Collaboratively Validate New Technology to Help Doctors More Accurately Diagnose Breast Cancer
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the University of Leeds in the UK through 2027, the two organizations announced today. Through a prior three-year partnership, 4D Path has already successfully completed three breast cancer clinical studies at Leeds with striking results. Cases from over ...
By 4D Path Inc.
-
Development of an antibacterial nanocomposite hydrogel for human dental pulp engineering
Hydrogel-based regenerative endodontic procedures (REPs) are considered to be very promising therapeutic strategies to reconstruct the dental pulp (DP) tissue in devitalized human teeth. However, the success of the regeneration process is limited by residual bacteria that may persist in the endodontic space after the disinfection step and contaminate the biomaterial. The aim of this work was to ...
By Adjuvatis
-
Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path
4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter, MD, MPH, MBA, has joined the company’s distinguished advisory board. Dr. Carter has a longstanding passion for applying emerging technologies across precision medicine, digital heath and AI applications to improve patient access to healthcare. ...
By 4D Path Inc.
-
4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images
4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT, Harvard Medical School and the University of Cambridge, has unveiled a faster, more efficient approach to cancer diagnosis and biomarker profiling with better accuracy that accelerates and democratizes precision medicine for optimized patient care and ...
By 4D Path Inc.
-
Thermo Fisher Scientific Expands GlobalAccess Sequencing Program
Thermo Fisher Scientific today announced the expansion of its GlobalAccess Sequencing Program to include laboratories working in oncology. Originally introduced to accelerate multi-institutional-led studies focused on SARS-CoV-2, the expanded program now provides support to labs facing significant constraints as a result of the global pandemic by offering faster access to comprehensive, ...
-
FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat
ImmunoCAP Specific IgE alpha-Gal Allergen Component test has been cleared by the U.S. Food & Drug Administration (FDA) for in vitro diagnostic use. Test results can aid specialists and other healthcare providers as they diagnose a patient's sensitization to the alpha-Gal carbohydrate found in mammalian (red) meat and assess his or her risk for an anaphylactic reaction. According to the ...
-
Selfdiagnostics SARS-CoV-2 IgM/IgG Antibody Assay Kit is a rapid, accurate and straightforward point-of-care test kit that qualitatively detects IgM and IgG antibodies against the virus that causes COVID-19.
The test detects specific SARS CoV2 IgG and IgM antibodies in the blood in response to a coronavirus infection. The detection of antibodies can be used to identify those who have already had contact with the virus. IgG may remain elevated for up to several months and possibly years, which could help determine who has been exposed to the coronavirus, even if a person did not exhibit any symptoms ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
-
Dako Collaborates on Review of Immunohistochemistry`s Impact on Prostate Diagnostics
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced the release of a new review paper titled "Immunohistochemistry in Prostate Pathology" that illustrates the significant impact immunohistochemistry (IHC) can have on diagnostic prostate pathology. The paper is co-authored by two leading global experts in prostate pathology: Glen Kristiansen, M.D., ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you